UCB’s Parkinson’s Drug Stalls As Curtain Comes Down On ORCHESTRA

Almost three years to the day, Novartis and UCB heralded a pact that could have been worth $1.5bn to the Brussels-based group for a first-in-class, small-molecule, alpha-synuclein misfolding inhibitor for Parkinson’s disease. However, after a Phase IIa fail, the development of minzasolmin has been terminated.